Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharma firm based in Chatham, has purchased a facility in Massachusetts that will house a vaccine development center, it announced this week.
The company said in a news release that the 40,000-square-foot site will become its Advanced Development Center for accelerated development and manufacturing of vaccines, including ones for COVID-19.
“We are excited to have taken the first step in vertically integrating more of our development activities, but, even more importantly, adding a manufacturing capability for clinical trial-quality vaccines,” CEO and President Seth Lederman said in a prepared statement. “We believe this provides Tonix with a competitive advantage, especially in the current COVID-19 environment in which more domestic development and manufacturing capacity is needed.”
It expects the facility to be operational within 24 months, with single-use bioreactors and purification suites with equipment meeting Good Manufacturing Practice production of vaccines for clinical trials, including sterile vaccines in glass bottles.
